Fig. 2
From: GMP-manufactured CRISPR/Cas9 technology as an advantageous tool to support cancer immunotherapy
CRISPR/Cas9-mediated editing of T-cell. Interaction between PD-1 receptor transcribed by T-cells and PD-L1 ligand expressed on cancer cells. Activation of PD1/PD-L1 checkpoint inhibits cytokine production and cytotoxic activity of T-cell (left). CRISPR/Cas9-mediated editing of the PD-1 sequence inhibits PD-1 expression allowing extracellular cytokines release and improving T-cell killing activity (right)